Precision Oncology in Practice: How Theranostics Personalizes Treatment - Report - MDSpire

Precision Oncology in Practice: How Theranostics Personalizes Treatment

  • By

  • May 11, 2025

  • 4 min

Share

Clinical Report: Precision Oncology in Practice: How Theranostics Personalizes Treatment

Overview

Expand to include examples of diagnostic imaging and targeted therapies used in theranostics.

Background

Cancer's heterogeneity necessitates personalized treatment strategies rather than a one-size-fits-all approach. Theranostics addresses this need by enabling clinicians to visualize specific molecular targets within tumors, allowing for targeted therapy that directly attacks malignant cells. This method not only improves treatment precision but also facilitates real-time monitoring of therapeutic effectiveness.

Data Highlights

Incorporate specific statistics or references to clinical studies demonstrating efficacy.

Key Findings

  • Theranostics tailors cancer treatment to the unique molecular profile of each patient.
  • Positron Emission Tomography-Computed Tomography (PET-CT) is used to visualize specific molecular targets in tumors.
  • Prostate cancer therapies utilizing PSMA targeting agents have shown notable decreases in tumor size.
  • Peptide Receptor Radionuclide Therapy (PRRT) effectively targets neuroendocrine tumors, leading to significant tumor reduction.
  • Patient selection for theranostic applications is based on the presence of specific molecular targets, ensuring optimal treatment efficacy.

Clinical Implications

Clinicians should consider incorporating theranostic approaches in cancer treatment to enhance personalization and improve patient outcomes. The integration of advanced imaging techniques with targeted therapies can lead to more effective treatment plans tailored to individual patient profiles.

Conclusion

Theranostics exemplifies the principles of precision oncology, offering a promising approach to cancer treatment that aligns therapeutic interventions with the unique characteristics of each patient's cancer. This strategy not only enhances treatment effectiveness but also paves the way for more personalized cancer care.

References

  1. Atlantic Health System, Overlook Medical Center, 2023 -- Theranostics is Making Big Leaps in Personalized Cancer Care
  2. The ASCO Post, 2016 -- Mutanome-Directed Immunotherapy: Finding the Best Treatment Match
  3. The ASCO Post, 2012 -- Oncologists Examine Promise vs Reality of Personalized Medicine
  4. NDA 215833/S-021, 2025 -- FDA Label Expansion for PSMA-Positive Patients
  5. The ASCO Post, 2024 -- NETTER-2 Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors
  6. The ASCO Post — National Cancer Policy Summit: Setting Priorities for the Next 3 Years
  7. NDA 215833/S-021
  8. NETTER-2 Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors - The ASCO Post
  9. SNMMI/ACNM Procedure Standard for Post-Treatment Imaging of 177Lu-based

Original Source(s)

Related Content